Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
So my final question re: issuing RNS for new 1st diversification wins --> mgt expect to issue one in next few months - great! I expect this is a "leather" based channel since its always been one of the first in the list for textual updates and also in the last RNS majors on this.
The leather area seems to be the closest major diversification channel 24/25/26 so for John to articulate in such a granular fashion I'm guessing orders are now very close indeed and Im suspecting was a key trade-off consideration for the loss of lower profitability detergent customer. He keeps waving his tan shoes everywhere but lets see the stilettos now!
Look SNG only have ONE asset - its not like AZN that has an RNS every other day almost - so slowly slowly, newsflows; its our turn soon for something big....it works after all! SNG moves slowly but COULD be back v. soon. Happy weekend team
My submitted question for monday;
The recent Canaccord Brokers report contains major capex 24E-26E. Presumably this is the expectation for a new European manufacturing facility even given the recent customer volume reduction announced in previous weeks. Please comment whether this is a strategic decision to encourage further European centric customer switching to existing ITX product ingredients or is this to ensure sufficient global plant capacity for hypothetical plant capacity demands from new diversification product wins?
However, Josh we now know SNG has an awakened pulse with possibly a new collaborative PP scientific partner and we await further insight / intel. on how this will play out and connect with other strategic dots...that's why some investors bagged a few more shares making sense and may pay out big time beyond your end of day perspective ('paper losses' that never crystallize)!
Just noticed ITX is now very active in highlighting sustainability/ECO/CO2/global warning/decarbonising etc issues over last 11-12 months of so - much more than I would have anticipated so lets see how that replays into the ne wweb site theme!
Further info. to add to the mix here: Guess who is a primary LinkedIn acquaintance of the UK HSA's chief scientific officer?
Rick Bright
Former Director of the Biomedical Advanced R&D Authority of Federal Government of the United States
I'm really hoping the coin has finally dropped about SNG001's PP bandwidth potential within the UK HSA (PP initiative team anyway). Now perhaps (hopefully) they finally realize that the UK investment cost of helping co-finance another good phase II/III to launch SNG's product is far cheaper than the probability weighted economic impact cost over the next 15 years (i.e. the alternative possible threat of 1.0%-3.0% of the population heading for bed blocked hospitals/ICU's and poss. lockdown mark 3/4 in worst case scenario). Surely a rapid PP deployment SNG001 home delivery service via amazon drones for selected @risk population / groups is much better than waiting 4-5 months before UK vaccine manufacturing crew can synthesize and bulk up version 12 of its RNA vaccine once they know the molecular sequence/structure and can design a work around vax with some poss. side effect/contamination risks that folks want to avoid?
Indeed - rapid deployment thx. PP potential without having to mess around with molecular biol/genetic sequencing etc to understand vaccine hot spots and emerging mutations/new epitope structures and 3D configurations of pesky respiratory viruses. Simply a no brainer eh? All SNG investors all spotted this one 3 years ago didn't we so why the new interest now?
IMPORTANT NOTE: PLEASE INVESTORS do not bomb her LinkedIn profile with views unless you have the sales navigator incognito LinkedIN paid premium version. She will see the interest and I may lose some future influence and traction.
Why? It could be to mitigate severe future egg on face that SNg001 was overlooked by many in government / medical establishments and HSA as a worst case PP
prevention measure for any further dangerous respiratory viral variants. And Doc you did not see my CSO email to UK HSA so have no clue the manner it was written, its contents and the authority in which it was sent so perhaps it has material influence....or you can ignore or contradict what I am saying here
Doc. A possibility is as I mentioned earlier in this thread (if you missed it): re: my outreach to UK HSA last October 23 concerning major PP risks via LinkedIN and direct email follow-up to the New CSO. UK HSA may believe they have been remiss in not opening any kind of dialogue/wider support/engagement with SNG at all before 2023. The CSO who I connected with is clearly very closely acquainted to the co-speaker at the event tomorrow - Amanda H and it looks a bit of an unlikely coincidence:
"I'm not getting too excited but FYI (importantly) I did connect on LinkedIn during Oct 23 with the new Director General Science and Research (CSO) at UK HSA to flag my serious concerns about emerging mutation cracks within the UK's wider PP vaccine and therapeutic strategy and mentioned SNG001 as a specific illustrative case of wider thx. agnostics being somewhat ignored at great potential future PP risk. I sent a detailed follow-up email at the time with full detail of said concerns. Amanda Horton is acquainted to the CSO in LinkedIn. Senior Scientist / Project Team Leader at UK Health Security Agency"
So this may have been one factor considered by the UK HSA to connect and converse with SNG team at the end of 2023. Its either genuine or possible risk mitigation for the CSO - no idea which until we know more tomorrow.
I'm not getting too excited but FYI (importantly) I did connect on LinkedIn during Oct 23 with the new Director General Science and Research (CSO) at UK HSA to flag my serious concerns about emerging mutation cracks within the UK's wider PP vaccine and therapeutic strategy and mentioned SNG001 as a specific illustrative case of wider thx. agnostics being somewhat ignored at great potential future PP risk. I sent a detailed follow-up email at the time with full detail of said concerns. Amanda Horton is acquainted to the CSO in LinkedIn. Senior Scientist / Project Team Leader at UK Health Security Agency
Dec 2021–Present 2 yrs 5 mos
Senior Scientist in the U.K. Antiviral & Therapeutics Task Force and current lead virologist of the antiviral lab team based at Porton Down. We conduct research into the efficacy of antivirals against SARS-CoV-2 variants, seasonal coronaviruses, influenza and other priority pathogens as part of the UK’s pandemic preparedness strategy.
The other connected point is that EU supply agreements may stipulate EU plant access to avoid potential for interruption of supply. That's why I think the Bod will do everything to invest in plant capacity as soon as contracts become highly visible